Nasal Microbiome Modulation for Chronic Rhinosinusitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current studies on the nasal microbiome in patients with chronic rhinosinusitis (CRS) and asthma lack consistency in evaluating bacterial abundance and diversity, failing to provide in-depth information on the functional effects of nasal microbiota.
Innovation Solution
The use of predictive functional profiling to evaluate sinonasal bacterial communities, identifying specific aspects of the microbiome for modulation to treat CRS and/or asthma, involves administering a composition that stimulates or inhibits the growth of specific bacterial genera, such as Corynebacterium and Peptoniphilus, in the nasal cavity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If conventional microbiome evaluation methods are used to assess bacterial abundance and diversity, then basic compositional data can be obtained, but in-depth information on functional effects of nasal microbiota cannot be provided
Solution Approach 1:
The patent introduces predictive functional profiling as an intermediary analytical layer between conventional microbiome composition assessment and functional effect determination. This mediator translates basic bacterial abundance data into inferred functional capabilities, enabling functional effect information to be obtained without directly measuring complex functional outputs.
Solution Approach 2:
The patent replaces direct functional measurement (complex mechanical/biological assays) with computational prediction methods. By substituting wet-lab functional assays with in-silico predictive profiling, the method obtains functional effect information while avoiding the complexity of direct functional measurement systems.
2Reliability
If the nasal microbiome is not modulated, then the existing microbial community structure is maintained, but treatment outcomes for CRS and asthma remain suboptimal
Solution Approach 1:
The patent changes the compositional parameters of the nasal microbiome by administering specific bacterial compositions. By altering the relative abundances and types of bacteria present (compositional parameter change), the treatment shifts the microbial community from a pro-inflammatory state to a more balanced state, thereby reducing harmful inflammatory effects and improving treatment reliability.
3Measurement precision
If bacterial growth is stimulated or inhibited without selective targeting, then general microbiome changes occur, but specific functional effects on CRS and asthma cannot be achieved
Solution Approach 1:
The patent applies local quality by formulating bacterial compositions with specific species or strains selected for their particular functional capabilities. Rather than using non-selective broad-spectrum approaches, the composition targets specific bacterial taxa known to produce beneficial functions (such as anti-inflammatory metabolites), thereby achieving precise functional effects while managing formulation complexity through rational selection.
Data Source
AI summary
Methods and compositions for treating sinusitis in a subject are provided. The methods include administering to the subject an effective amount of a composition that stimulates growth or activity of a genus of bacteria that is decreased relative to a control subject not having sinusitis and/or inhibiting growth or activity of a genus of bacteria that is increased relative to the control subject.